Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
UnitedHealthcareCommercial · Prior Auth · Medical Benefit Drug Policy · Genetics, Endocrinology, Pediatrics +1 moreMedium impact

Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)

Effective date
Dec 1, 2026
Identified
Nov 7, 2026

Summary

UnitedHealthcare added Genglycos (pariglasgene brecaparvovec-opnr) to its Review at Launch program for commercial members, effective 2026-12-01, so some members may not be eligible for coverage at this time. Coverage is limited to patients aged 8 or older with glycogen storage disease type Ia who meet all listed criteria, including confirmed diagnosis, current cornstarch therapy, no detectable AAV8 antibodies, no prior gene therapy, specialist prescribing, and no planned inpatient admission solely to administer the drug. Authorization is limited to one lifetime treatment and no more than 45 days from approval.

Get alerts when payers change rules like this one

We check UnitedHealthcare and other payers every day and email you when a change matches your specialty and state.

Get UnitedHealthcare alertsPolicy Monitoring is free. No card required.

What to do

Action · 4 steps
01By 2026-12-01: Billing team and providers should review the Review at Launch policy for new-to-market medications and the Genglycos criteria before scheduling any Genglycos infusion for commercial members.
02Before scheduling, confirm each patient meets all criteria (age 8 or older, GSDIa diagnosis documented by G6PC variant testing or liver biopsy, current cornstarch regimen, AAV8 antibody status, no prior gene therapy, metabolic specialist prescribing, no inpatient admission solely for administration, FDA-labeled dosing) and obtain authorization covering one treatment, valid for no more than 45 days from approval.
03Front desk and intake staff should collect and attach the required medical records and lab values to the authorization request, and charge entry should reflect the authorized date window so claims match the approval.
04Watch for further UnitedHealthcare notices on coverage eligibility under this program.

Original notice

Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)
uhcprovider.com · Always check the source before changing claims.
View original ↗

Related changes

See all UnitedHealthcare changes →
Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)MediumEffective Dec 1, 2026 · Medical Benefit Drug PolicyGenglycos ™ (Pariglasgene Brecaparvovec-Opnr)MediumEffective Dec 1, 2026 · Medical Benefit Drug PolicyGenglycos ™ (Pariglasgene Brecaparvovec-Opnr)MediumEffective Dec 1, 2026 · Medical Benefit Drug PolicyGenglycos ™ (Pariglasgene Brecaparvovec-Opnr)LowEffective Dec 1, 2026 · Medical Benefit Drug PolicyBrowse every UnitedHealthcare change in the policy list

Related policy hubs

UnitedHealthcare policiesGeneticsEndocrinologyPediatricsPharmacy

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account